Newsflash

Press Release – NEURO-BIO ATTRACTS OVER $3 MILLION IN SERIES A INVESTMENT TO DEVELOP A NEW APPROACH TO ALZHEIMER’S DISEASE Click here for the Neuro-Bio press release 17th March

Author Archive

European Patent Granted

We are pleased to announce that the European Patent Office intends to grant our application for a patent – Neurodegenerative Disorders Neuro-Bio Ltd Application No. 14736948.2

Susan Greenfield’s upcoming talks

Friday 19 May 2017 at 10:00 – World Precision Medicine Congress 2017, Business Design Centre, 52 Upper Street, Islington, London N1 0QH – Precision medicine and neurodegenerative disease
Tuesday 6 June/Wednesday 7 June 2017 – OECD Forum Paris, France – Details still to be finalised

Best of Luck to Emily Smith

Emily Smith, PA to Neuro-Bio Ltd CEO, Susan Greenfield, left in November 2016 on maternity leave. Neuro-Bio would like to congratulate her and her partner and wish them the very best of luck on becoming parents to the lovely Amelia. Emily will be returning in August 2017.

BioNewsRound Award finalist!

Neuro-Bio Ltd are delighted to announce that we have been short listed for the BioNewsRound Award. Our CEO, Susan Greenfield will be presenting a short presentation at the ON Helix Welcome Reception on 27th June. You can find out more information on their website, here.

Alzheimer’s Disease: Defusing The Bomb By 2025

Published in In Vivo Beyond Beta-Amyloid  The US FDA has approved six drugs to treat Alzheimer’s symptoms, all of which work by increasing the amount of neurotransmitters in the brain, helping nerve cells in the brain to communicate. These approved therapies are: Razadyne (galantamine), Exelon (rivastigmine), Aricept, Namenda,Namzaric (memantine + donepezil) and Cognex, which is no longer widely sold in the US. None of these drugs prevent or treat the cause of Alzheimer’s, nor do they slow progression of the disease.

BBC Business LIVE

Baroness Susan Greenfield will be on BBC Business Live on Monday 16th May, talking about Alzheimer’s Disease and Neuro-Bio Ltd. If you missed this, you can catch up by clicking, here.  

Best of Luck to Dr Garcia-Rates

Dr Sara Garcia-Rates left Neuro-Bio Ltd in January 2016 on Maternity leave. Neuro-Bio would like to congratulate her and her husband, and wish them the very best of luck to becoming parents. Dr Garcia-Rates will be returning to Neuro-Bio Ltd in July 2016.